Search results for Kras

Latest updates for Kras

Fresh curated links around KRAS are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Post angles to try

Share the most useful takeaway for your audience.

Turn one article into a quick practical checklist.

Ask your audience how this shift affects their work.

Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

fiercebiotech.com /4 days ago

Kura posts Krazati combo data on drug designed to unleash KRAS inhibitors’ potential

Kura Oncology has published early data on darlifarnib in combination with Bristol Myers Squibb’s Krazati, linking the drug candidate to response rates of up to 69% when given with...

Read source

journals.plos.org /1 month ago

Computational insights on the molecular interplay between KRas (G12D mutation) and SOS1 modulated by the inhibitor BI-34...

by Juan Zeng, YiXuan Lan, Fei Xia Ras proteins are prominent oncogenes, with KRas mutations found in approximately 80% of cancer cells harboring Ras mutations. The mechanism by wh...

Read source

genengnews.com /1 month ago

Landmark Pancreatic Cancer Trial Highlights Promise of RAS-Targeting Daraxonrasib

Daraxonrasib improved survival in metastatic pancreatic cancer in the Phase III RASolute 302 trial, showing activity across diverse RAS variants. As the field turns its attention t...

Read source

labiotech.eu /1 week ago

RAS inhibition enters its second wave

Delve into the field of RAS inhibitors, an area of biotechnology that is increasingly diversifying to tackle pancreatic cancer, among other cancers. The post RAS inhibition enters...

Read source

journals.plos.org /1 month ago

Constitutively active RAS prolongs Cdc42 signalling, while MAPK signalling is attenuated during fission yeast mating

by Emma J. Kelsall, Akatsuki Kimura, Ábel Vértesy, Kornelis R. Straatman, Mishal Tariq, Raquel Gadea, Chandni Parmar, Gabriele Schreiber, Shubhchintan Randhawa, Takashi Y. Ida, Cyr...

Read source

jurnalul.ro /1 month ago

Descoperire majorДѓ Г®n lupta Г®mpotriva cancerului: tratamente pentru mutaИ›ia KRAS

CercetДѓtorii fac progrese importante Г®n dezvoltarea unor tratamente care vizeazДѓ proteina KRAS, o mutaИ›ie implicatДѓ Г®n unele dintre cele mai letale forme de cancer, inclusiv...

Read source

gastrojournal.org /6 days ago

Targeting oncomucin-driven immunosuppression improves the efficacy of K-rasG12D inhibition in pancreatic cancer

Oncogenic de novo mucins (oncoMUCs; MUC4, MUC16, and MUC5AC) are progressively upregulated in pancreatic ductal adenocarcinoma (PDA). While their individual cell-intrinsic roles ha...

Read source

fiercebiotech.com /1 month ago

AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib, last Monday, Revolution Medicines is not resting on its laurels. The Bay Area biotec...

Read source

ekbis.sindonews.com /4 weeks ago

KRAS Ambil Bagian dalam Hilirisasi Nasional Fase 2: Perkuat Kedaulatan Industri Baja Nasional

PT Krakatau Steel (Persero) Tbk/Krakatau Steel Group (KRAS) hadir sebagai pilar utama dalam agenda ini melalui dua proyek investasi yang berlokasi di Cilegon.

Read source

fiercebiotech.com /1 month ago

AbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition

AbbVie has agreed to help finance a KRAS inhibitor from Kestrel Therapeutics in a deal that could hit up to $1.45 billion in value and end with AbbVie buying the company outright.

Read source

rna-seqblog.com /1 month ago

IMA histology should trigger RNA sequencing in NSCLC – here’s why

RNA sequencing enables detection of NRG1 fusions in invasive mucinous adenocarcinoma, ensuring accurate molecular profiling and identification of actionable targets often missed by...

Read source

bioengineer.org /2 weeks ago

Unraveling Raf-MEK-ERK Pathway in Prostate Cancer

The landscape of cancer therapy has been profoundly revolutionized by clinical interventions targeting the MAPK (Mitogen-Activated Protein Kinase) pathway, a critical signaling cas...

Read source

fiercebiotech.com /1 month ago

Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of...

Read source

jvir.org /4 weeks ago

Abstract No. LBA15 Liquid Biopsy Detection of TP53, mGSTP1, and mRASS1Fa from Circulating Tumor DNA Improves the Non-inv...

Alpha fetoprotein (AFP) is used to screen high risk patients for hepatocellular carcinoma (HCC) but has limited sensitivity, demanding the identification of new biomarkers. This st...

Read source

bioengineer.org /1 month ago

KMT2C/D Loss Creates Targetable Cancer Weaknesses

In recent years, the intricate landscape of cancer biology has increasingly highlighted the pivotal role of epigenetic regulators in tumor development and progression. Among the va...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.